实用医学杂志
實用醫學雜誌
실용의학잡지
THE JOURNAL OF PRACTICAL MEDICINE
2014年
5期
789-791
,共3页
张立娜%韩婷婷%李宏奇%王颖杰%吴伟章%夏廷毅
張立娜%韓婷婷%李宏奇%王穎傑%吳偉章%夏廷毅
장립나%한정정%리굉기%왕영걸%오위장%하정의
脊柱疾病%脊柱转移癌%靶中靶放疗%疼痛
脊柱疾病%脊柱轉移癌%靶中靶放療%疼痛
척주질병%척주전이암%파중파방료%동통
Spinal neoplasms%Spinal metastases%Target in target radiotherapy%Pain
目的:比较分析剂量递增靶中靶放疗(TIT)与常规放疗脊柱转移癌的治疗结果。方法:采用放射治疗90例椎体转移癌患者(病灶118处),靶中靶放疗52例(病灶63处),计划靶体积(PTV)30~40 Gy,大体靶体积(GTV)50~60 Gy,15~25次。常规放疗38例(病灶55处),PTV 30~40 Gy,10~20次。结果:两组止痛有效率分别为90.4%、81.6%,但止痛疗效无差异。近期治疗部位改善分别为31处(49.2%)、25处(45.5%),稳定状态28处(44.4%)、20处(36.3%),恶化4处(6.35%)、10处(18.1%)。1年局部控制率、生存率分别为84.7%、68.6%,49.4%、32.2%,差异均有显著性。急性不良反应主要有血液毒性,两组无统计学差异。结论:靶中靶放射治疗脊柱转移癌是一种更安全有效的局部治疗手段,具有更好的疗效和副反应少的特点。
目的:比較分析劑量遞增靶中靶放療(TIT)與常規放療脊柱轉移癌的治療結果。方法:採用放射治療90例椎體轉移癌患者(病竈118處),靶中靶放療52例(病竈63處),計劃靶體積(PTV)30~40 Gy,大體靶體積(GTV)50~60 Gy,15~25次。常規放療38例(病竈55處),PTV 30~40 Gy,10~20次。結果:兩組止痛有效率分彆為90.4%、81.6%,但止痛療效無差異。近期治療部位改善分彆為31處(49.2%)、25處(45.5%),穩定狀態28處(44.4%)、20處(36.3%),噁化4處(6.35%)、10處(18.1%)。1年跼部控製率、生存率分彆為84.7%、68.6%,49.4%、32.2%,差異均有顯著性。急性不良反應主要有血液毒性,兩組無統計學差異。結論:靶中靶放射治療脊柱轉移癌是一種更安全有效的跼部治療手段,具有更好的療效和副反應少的特點。
목적:비교분석제량체증파중파방료(TIT)여상규방료척주전이암적치료결과。방법:채용방사치료90례추체전이암환자(병조118처),파중파방료52례(병조63처),계화파체적(PTV)30~40 Gy,대체파체적(GTV)50~60 Gy,15~25차。상규방료38례(병조55처),PTV 30~40 Gy,10~20차。결과:량조지통유효솔분별위90.4%、81.6%,단지통료효무차이。근기치료부위개선분별위31처(49.2%)、25처(45.5%),은정상태28처(44.4%)、20처(36.3%),악화4처(6.35%)、10처(18.1%)。1년국부공제솔、생존솔분별위84.7%、68.6%,49.4%、32.2%,차이균유현저성。급성불량반응주요유혈액독성,량조무통계학차이。결론:파중파방사치료척주전이암시일충경안전유효적국부치료수단,구유경호적료효화부반응소적특점。
Objective To analyze the result of dose-escalated radiotherapy vs conventional radiotherapy for spinal metastases. Methods Ninety patients (118 lesions) underwent radiotherapy..There were 52 patients (63 lesions) in target in target radiotherapy (TIT) receiving PTV 30~40 Gy, GTV 50~60 Gy/15~25 f. 38 patients (55 lesions) received PTV 30~40 Gy/10~20 f in the conventional radiotherapy. Results The overall responses were 90.4% and 81.6%,respectively.but no significant difference was found. There were 31 and 25 improved lesions, 28 and 20 steady lesions, 4 and 10 worsening lesions,in two goups, respectively. 1-year local control rates and survival were 84.7%vs 68.6%and 49.4%vs 32.2%, respectively. The significant differences were found in 1-year local control rates and survival. The main acute adverse reactions were mainly hematologic toxicities , no significant difference was found. Conclusion TIT for spinal metastases is a more safe and effective treatment, with better efficacy and fewer side-reactions.